Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs DBVT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: VNDA 4 – 1 DBVT (1 Tie) Matrix Metrics: VNDA 7 – 3 DBVT

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas DBVT carries 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin).

  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile DBVT trades in a Neutral technical trend (SURGE options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs DBVT
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
DBVT NASDAQ
DBV Technologies S.A.
Biological Products, (No Disgnostic Substances)
$10.26
-6.85% 1D
Market Cap $682.5M
TTM Revenue $3.7M
Forward P/E N/M
Beta / 30D Vol 1.17β · 77% Vol
Unified Composite Score
30.9 / 100 SELL
Tech 15.0 Fund 36.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.9 · SMA20: $10.28 · SMA50: $10.78

6-Pillar Scorecard Institutional Category Breakdown (VNDA 4 – 1 DBVT)

Columns: Metric · VNDA · DBVT
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x N/M
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 140.3x
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% -42.9%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $3.7M
Market Cap $238.9M $682.5M
3. Profitability & Quality VNDA
Gross Margin 93.6% 100.0%
Operating Margin -77.6% -5577.0%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -205.8%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$192M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $158M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DBVT
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 163.3% (75th %ile) 64.5% (13th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (7) vs DBVT (3)
Institutional Metric VNDA DBVT Criterion Row Edge
Market Capitalization
Scale
$238.9M $682.5M Larger Scale DBVT
Trailing P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% -42.9% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% -5577.0% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin DBVT
Return on Equity (ROE)
Capital Efficiency
-82.5% -205.8% Higher ROE VNDA
52-Week Range Position
Momentum
4% ($4–$10) 9% ($9–$26) Stronger Trend DBVT
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.17β · 77% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 30.9 / 100 (SELL) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M $3.7M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 140.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$192M ($158M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DBVT +19.2 pp
VNDA: -5.83% · DBVT: +13.37%
3M Horizon DBVT +1.15 pp
VNDA: -30.24% · DBVT: -29.09%
6M Horizon VNDA +7.7 pp
VNDA: -37.58% · DBVT: -45.28%
1Y Horizon VNDA +8.88 pp
VNDA: -12.56% · DBVT: -21.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue DBVT Revenue VNDA Op. Margin DBVT Op. Margin Margin Leader
FY2018 $190M N/A 11.3% N/A VNDA
FY2019 $230M $10M 10.0% -1162.8% VNDA
FY2020 $250M $10M 11.0% -1408.7% VNDA
FY2021 $270M $10M 15.7% -1727.6% VNDA
FY2022 $250M $0M 2.5% -1994.9% VNDA
FY2023 $190M $20M -7.2% -486.0% VNDA
FY2024 $200M $0M -20.5% -2808.7% VNDA
FY2025 $220M $10M -70.0% -2609.2% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DBVT SURGE
5d in phase · OBV ACCUMULATION
Current IV 64.5%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DBVT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DBVT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $682.5M market capitalization and -5577.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs DBVT Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over DBV Technologies S.A. (DBVT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas DBVT carries 30.9/100 (SELL) at $10.26 (N/M Forward P/E, -5577.0% operating margin). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile DBVT trades in a Neutral technical trend (SURGE options phase, RSI 47.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with DBVT at -42.9% YoY revenue growth and +0.0% YoY earnings growth on $3.7M TTM revenue (100.0% gross margin, -5577.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while DBVT shifted +0.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DBVT.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas DBVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 140.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus DBVT (-205.8% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, DBVT carries 64.5% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.17β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.